Vora A, Goulden N, Wade R et al (2013) Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol 14(3):199–209
CAS
Article
PubMed
Google Scholar
Bhojwani D, Sabin ND, Pei D et al (2014) Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol 32(9):949–959
CAS
Article
PubMed
PubMed Central
Google Scholar
Schuitema I, Deprez S, Van Hecke W et al (2013) Accelerated aging, decreased white matter integrity, and associated neuropsychological dysfunction 25 years after pediatric lymphoid malignancies. J Clin Oncol 31(27):3378–3388
Article
PubMed
Google Scholar
Van der Plas E, Nieman BJ, Butcher DT, Hitzler JK, Weksberg R, Ito S, Schachar R (2015) Neurocognitive late effects of chemotheapy in survivors of acute lymphoblastic leukemia: focus on methotrexate. J Can Acad Child Adolesc Psychiatry 24(1):25–32 (Winter)
PubMed
PubMed Central
Google Scholar
Raghavendra S, Nair MD, Chemmanam T, Krishnamoorthy T, Radhakrishnan VV, Kuruvilla A (2007) Disseminated necrotizing leukoencephalopathy following low-dose oral methotrexate. Eur J Neurol 14(3):309–314
CAS
Article
PubMed
Google Scholar
Gonzazlez-Suarez I, Aquilar-Amat MJ, Triqueros M, Borobia AM, Cruz A, Arpa J (2014) Leukoencephalopathy due to oral methotrexate. Cerebellum 13(1):178–183
Article
Google Scholar
Radtke S, Zolk O, Renner B et al (2013) Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity and outcome in childhood acute lymphoblastic leukemia. Blood 121(26):5145–5153
CAS
Article
PubMed
Google Scholar
Badke C, Fleming A, Iqbal A, Khilji O, Parhas S, Weinstein J, Morgan E, Hiiya N (2015) Rechallenging with intrathecal methotrexate after developing subacute neurotoxicity in children with hematologic malignancies. Pediatr Blood Cancer 63(4):723–726
Article
PubMed
Google Scholar
Lobel U, Trah J, Escherich G (2015) Severe neurotoxicity following intrathecal methotrexate with nitrous oxide sedation in a child with acute lymphoblastic leukemia. Pediatr Blood Cancer 62(3):539–541
CAS
Article
PubMed
Google Scholar
Chamberlin ME, Ubagai T, Mudd SH, Wilson WG, Leonard JV, Chou JY (1996) Demyelination of the brain is associated with methionine adenosyltransferase I/III deficiency. J Clin Invest 98(4):1021–1027
CAS
Article
PubMed
PubMed Central
Google Scholar
Vijayanathan V, Gulinello M, Ali N, Cole PD (2011) Persistent cognitive deficits, induced by intrathecal methotrexate, are associated with elevated CSF concentrations of excitotoxic glutamate analogs and can be reversed by an NMDA antagonist. Behav Brain Res 225(2):491–497
CAS
Article
PubMed
Google Scholar
Surtees R, Clelland J, Hann I (1998) Demyelination and single-carbon transfer pathway metabolites during the treatment of acute lymphoblastic leukemia: CSF studies. J Clin Oncol 16(4):1505–1511
CAS
PubMed
Google Scholar
Suzuki K, Doki K, Homma M et al (2009) Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 67(1):44–49
CAS
Article
PubMed
PubMed Central
Google Scholar
Deacon R, Lumb M, Perry J et al (1978) Selective inactivation of vitamin B12 in rats by nitrous oxide. Lancet 2(8098):1023–1024
CAS
Article
PubMed
Google Scholar
McColl KE (2009) Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 104(Suppl 2):S5–S9
CAS
Article
PubMed
Google Scholar
Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. http://www.medicinescomplete.com. Accessed 5 Feb 2016